Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers

Learn more about:
Related Clinical Trial
Transcriptomic Responses for the Identification of Pathogens Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants Commercial Typhoid Tests Validation Trial Commercial Typhoid Tests Validation WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial) Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old) Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old) Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort Safety and Immunogenicity of Typhax, a Typhoid Vaccine Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III) Investigating Enteric Fever – Salmonella Typhi and Paratyphi Challenge Study Induction of Gut Permeability by an Oral Vaccine Studies of Immune Responses to Orally Administered Vaccines in Developing Country Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants Typhoid Fever: Combined vs. Single Antibiotic Therapy Vaccines Against Salmonella Typhi Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults CVD 909 Vi Prime Boost Study Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso Understanding Typhoid Disease After Vaccination Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood Global Genomic and Proteomic Profiling of African Children With Typhoid Fever

Brief Title

Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers

Official Title

Phase 4 Observational Prospective Cohort Study to Assess the Safety of Vivotif at Different Release Titers Among Travelers

Brief Summary

      This is a multicenter (at travel clinics), phase 4 observational prospective cohort study in
      healthy adult male and female travelers for whom typhoid vaccination with Vivotif is
      recommended, as per standard practice.
    

Detailed Description

      This is a multicenter (at travel clinics), phase 4 observational prospective cohort study in
      healthy adult male and female travelers for whom typhoid vaccination with Vivotif is
      recommended, as per standard practice.

      The study will enroll 950 subjects who will be randomized at a ratio of 1:1 into two groups,
      A and B, of 475 subjects each. Group A will receive 6.9-10.0 x109 CFU/capsule and Group B
      will receive 4.0-6.8 x109 CFU/capsule, respectively.

      All subjects will receive four doses of Vivotif. One dose per subject will be administered on
      Days 1, 3, 5 and 7.

      Investigators, subjects and all personnel involved in running the study will not be aware of
      the actual release titer associated with the distributed lots. Blinding is maintained using
      the commercial packaging that does not include the actual value of the release titer.
    


Study Type

Observational


Primary Outcome

The occurrence of any AE up to two weeks after the scheduled final vaccine dose

Secondary Outcome

 The distribution of the solicited Adverse Reactions

Condition

Typhoid Fever

Intervention

Vivotif

Study Arms / Comparison Groups

 Group A
Description:  Vivotif 6.9-10.0 x109 CFU/capsule

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Biological

Estimated Enrollment

855

Start Date

August 26, 2015

Completion Date

February 21, 2017

Primary Completion Date

October 6, 2016

Eligibility Criteria

        Inclusion Criteria:

          1. Subjects are male or female aged ≥ 18 years at time of dosing

          2. Subjects are travelers attending travelers' vaccination clinics

          3. Subjects are eligible for typhoid vaccination, according to standard practice

          4. Subjects are expected to be able to provide follow-up information

          5. Subjects have an expected travel departure date more than 21 days after enrollment (to
             enhance follow-up by ensuring subjects remain in the US during the AE collection
             period)

          6. Subjects must sign a written informed consent

        Exclusion Criteria:

          1. Subjects with a known hypersensitivity to any component of the vaccine or the enteric
             coated capsule

          2. Subjects deficient in their ability to mount a humoral or cell-mediated immune
             response due to either a congenital or acquired immunodeficient state including
             treatment with immune-suppressive or antimitotic drugs

          3. Subjects with an acute febrile illness

          4. Subjects with acute gastrointestinal (GI) illness

          5. Subjects who are receiving medications with antibacterial activity (including
             proguanil) at the time of enrollment

          6. Subjects with other contraindications as determined by the site investigator
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT02391909

Organization ID

VIV-PASS-01


Responsible Party

Sponsor

Study Sponsor

Emergent BioSolutions


Study Sponsor

, , 


Verification Date

March 2020